Nidanilimab clinical trials
Also written Nadunolimab and CAN04.
How each study uses nidanilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nidanilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 3
Cantargia AB (4) · M.D. Anderson Cancer Center (1) · Robert Samstein (1) · Dan Feng (1)
Studies
Open first, then newest update. How each study uses nidanilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06548230Written as Nadunolimab
- Immunoprevention for High-risk Lung LesionsRecruitingPhase 2Robert SamsteinNCT07284485Written as Nadunolimab
- Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRCRecruitingPhase 1/2Dan FengNCT07281716Written as Nadunolimab
- Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.CompletedPhase 1/2Cantargia ABNCT05181462Written as Nadunolimab
- A First-in-Human Study of CAN04 in Patients With Solid Malignant TumorsCompletedPhase 1/2Cantargia ABNCT03267316Written as CAN04
- A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid TumorsCompletedPhase 1Cantargia ABNCT04452214Written as CAN04
- A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal AdenocarcinomaCompletedPhase 1Cantargia ABNCT04990037Written as CAN04
Given beside what is tested · 1 — nidanilimab is usual care or a partner of the new treatment
Codes
What other systems call nidanilimab · ClinicalTrials.gg INT017378
- UNII (FDA) ND296JF21INIDANILIMABOne source FDA
- NCI Thesaurus C153375NidanilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ND296JF21I | NIDANILIMAB | One source FDA |
| NCI Thesaurus | C153375 | Nidanilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.